HepG2 (Human hepatocellular liver carcinoma cell line) Nuclear Lysate (ab14660)
- Product nameHepG2 (Human hepatocellular liver carcinoma cell line) Nuclear LysateSee all HepG2 lysates ...
- General notesWe recommend aliquoting the extracts into single use fractions and then storing them.
- Tested applicationsEMSA, WB more details
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: None
Constituents: 20% Glycerol, 20mM HEPES, 1mM Magnesium Chloride, 100mM KCl, 0.5mM PMSF, 0.5mM DTT. pH 7.9
- Concentration information loading...
- Research Areas
- BackgroundHepatitis B virus (HBV) is the major cause of acute and chronic hepatitis, leading to progressive development of necroinflammatory changes in the liver, which can result in cirrhosis and hepatocellular carcinoma. Although the development of an effective vaccine to prevent HBV infection has shown promising results and should lead to its eventual eradication, antiviral chemotherapy remains the only effective method to prevent the progression of the disease in chronic carriers. Therefore, the development of new antiretroviral agents active against HBV is needed. HepG2 cells have an epithelial morphology and are thought to be a very useful model to study HBV virus replication via transfection. Cells are also used for cancer and apoptosis studies (in particular signalling pathway studies).
Our Abpromise guarantee covers the use of ab14660 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|EMSA||EMSA: Use at an assay dependent dilution.|
|WB||WB: Use at an assay dependent dilution.|
References for HepG2 (Human hepatocellular liver carcinoma cell line) Nuclear Lysate (ab14660)
ab14660 has not yet been referenced specifically in any publications.